The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab).

The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.

NEW YORK — Digital pathology firm Gestalt Diagnostics said on Monday that it has raised $7.5 million through a Series A financing round. The round was led by Cowles Ventures, TVF Funds, Inland Imaging ...

The first $25 million tranche was funded at close and used to retire Exagen's existing term debt facility with Innovatus Capital Partners.

The firm said that its overall revenues rose 2 percent year over year and 4 percent on an organic basis with a smaller increase in its life sciences revenues.

Last week, readers were most interested in a story about Akoya's collaboration to identify markers predictive of response to checkpoint inhibitor therapy.

The company said during a conference call following release of its Q1 2025 results that it purchases roughly 80 percent of ...

In one case a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other a firm paid and received kickbacks for unnecessary genetic testing.

The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease ...

SSID Group said that the assets acquired in the deal will complement its gastric health portfolio and let it offer a broader range of tests to US labs.

NEW YORK — Swiss healthcare firm Roche said Monday that it intends to invest $50 billion over the next five years into expanding its footprint in the US. According to Roche, the money will be used in ...

The project will use Akoya's PhenoCode Discovery IO60 Panel to look at matched pairs of immuno-oncology exceptional responders and hyper-progressors.